Biohaven just had its best day in years. Specifically, the Vyglxia resubmission won FDA acceptance for review. Shares jumped 39 percent in premarket trading to $16.35. Ultimately, the rally marked one of the biggest single day gains in years.
The news came in a regulatory filing on October 22, 2026. Biohaven said the FDA considers the resubmission a complete response. In response, it answers the agency’s November 2025 rejection letter. The company previously added new positive supportive analyses to the application.
Vyglxia, also known as troriluzole, still targets spinocerebellar ataxia. SCA is a rare disease of the nervous system that runs in families. It causes a progressive loss of muscle control and coordination. No FDA approved treatment exists for the condition.
Doctors diagnose SCA through genetic testing as well as movement exams. The patients the Vyglxia resubmission aims to help may first notice unsteady walking or slurred speech. Coordination fades as the years pass. Physical therapy can help manage symptoms, but it cannot stop the disease.

This decision follows a long regulatory road. In July 2023, the FDA refused to file the first application. Then Biohaven previously tried again in late 2024 with three year real world evidence. The agency rejected that bid in November 2025 over study design flaws.
However, the 2025 rejection stung. Agency reviewers said the real world study met its targets but suffered from potential bias. Regulators also previously flagged poor study design. Biohaven cut research spending by about 60 percent after the setback.
The spending cuts previously showed how much rode on the Vyglxia resubmission. Biohaven held about 270.5 million dollars in cash and securities at mid year. A failed program would have forced harder choices. The acceptance gives the company breathing room. Management can now plan around a 2027 decision.
The new filing tries to answer those concerns. Biohaven says the added analyses support the main study findings. Next, the FDA will convene an advisory committee. Outside experts will weigh the drug risks and benefits.
Regulators set a target decision date for the first quarter of 2027. The meeting date will come in the near term. William Blair analyst Myles Minter covers the stock. Clearly, investors will watch the AdCom closely.
The advisory committee plays a key role in FDA decisions on the Vyglxia resubmission. Outside scientists and patient representatives review the evidence. Then they vote on whether benefits outweigh risks. The agency usually follows their advice, but the vote does not bind the agency. A positive vote would lift Biohaven odds considerably.

The disease community has waited years for progress. SCA slowly robs patients of balance, speech and movement. Families face a steady decline with no approved medicine. The wait weighs on caregivers too. Still, an FDA review brings fresh hope, not a promise.
Rare disease drug reviews carry extra weight. Small patient populations make big trials hard to run, which is why the Vyglxia resubmission leans on real world evidence. Regulators sometimes accept real world evidence to fill the gap. Therefore, that flexibility is exactly what Biohaven is counting on. The panel will test whether the data holds up.
Morningstar reported the 39 percent premarket jump on Thursday. Biotech stocks often swing hard on regulatory news. Readers can compare with another recent FDA decision in our FDA clears Hibsago coverage. Still, acceptance for review is not approval. The stock cooled after the opening surge. Shares later traded up about 25 percent on the day. The long term story now rests on the 2027 decision. Patience will matter more than Thursday excitement as the Vyglxia resubmission moves toward 2027.
What happens next is procedural. The panel will meet in the coming months. The final decision then lands by early 2027. Biohaven must still prove the drug works. In other words, the review is a door opening, not a finish line.
Biohaven operates as a clinical stage company from New Haven, Connecticut. An approval would make Vyglxia the company’s first commercial product. The company has chased this approval for years. Ultimately, a green light would transform its fortunes.
The Vyglxia resubmission gives Biohaven a second chance that few expected. For families who measure hope in years, not quarters, this week brought something they have not had in a long time: a date to wait for. This article reports the news only and is not medical advice.
